Zerion Pharma and Hovione extend partnership to cover use of the Dispersome(R) technology platform in nutraceuticals
PR97504
LISBON, Portugal, Aug. 23, 2022 /PRNewswire=KYODO JBN/ --
Hovione and Zerion Pharma A/S (Zerion) today announced an extension of their
collaboration on Zerion's Dispersome(R) technology into the
nutraceutical/dietary supplements field. Many dietary supplements suffer from
low solubility. This results in poor bioavailability and consequently limits
the physiological effect of the supplement. To overcome these limitations, the
two companies will collaborate and apply the solubility enhancing Dispersome(R)
technology for the development and commercialization of certain nutraceutical
products.
The first product candidate selected for joint development is an antioxidant
with multiple health benefits and known for its extremely low solubility and
bioavailability. By applying the Dispersome(R) technology, Zerion has been able
to demonstrate significant solubility improvements of this antioxidant. Under
their collaboration, Hovione and Zerion will now upscale and develop commercial
formulations of the antioxidant using the Dispersome(R) platform and make these
products available for distribution by partners globally. Under the terms of
the collaboration agreement, the two companies will share income from the
commercialization of these products according to their respective contributions.
In addition to the joint development projects, Zerion has granted Hovione an
exclusive license to exploit the Dispersome(R) technology for other
nutraceuticals/dietary supplements. In return, Hovione will pay Zerion license
fees and royalties on sales of the licensed products.
"The low oral bioavailability of some of the health-promoting nutraceutical
compounds is a well-known challenge. The problem is compounded by the fact that
some of the solutions used in pharma cannot be used in foods." says Jean-Luc
Herbeaux, CEO of Hovione. He adds: "Hovione is thrilled to be Zerion´s
exclusive partner for the application of Dispersome(R) to the fields of
nutraceuticals and dietary supplements. The Dispersome(R) platform and its
enabling ingredient – beta-lactoglobulin or BLG – afford formulators new
options which address unmet needs of the industry."
"I am extremely pleased with this extension of our collaboration", says Ole
Wiborg, CEO of Zerion and continues: "The Dispersome® technology is actually
very well suited for use in dietary supplements because it employs BLG as its
solubility enabling component. BLG is a sustainable natural material and in
itself a beneficial nutritional product that we source in high quality from
Arla Food Ingredients. Since we as a company only have limited resources to
exploit these promising applications of the Dispersome(R) technology in the
nutraceutical field, the collaboration with Hovione is a win/win situation."
In February 2022, Zerion and Hovione announced a strategic partnership aimed at
commercializing the Dispersome(R) technology within the drug development field.
Under this partnership, Hovione and Zerion are offering pharma and biotech
companies worldwide access to an innovative drug delivery platform combined
with an unparalleled experience in formulation development, scale up and GMP
manufacturing. This unique combination provides customers in the pharma
industry with a line of sight over the entire drug development life cycle from
the preclinical phase to commercial drug product.
About Hovione
Hovione is an international company with over 60 years of experience as a
Contract Development and Manufacturing Organization (CDMO) with a fully
integrated offering of services for drug substance, drug product intermediate
and drug product. The company has four FDA inspected sites in the USA,
Portugal, Ireland and China and development laboratories in Lisbon, Portugal
and New Jersey, USA. Hovione provides pharmaceutical customers services for the
development and compliant manufacture of innovative drugs, including highly
potent compounds, and customized product solution across the entire drug life
cycle. In the inhalation area, Hovione offers a complete range of services,
from API, formulation development and devices. Hovione´s culture is based on
innovation, quality and delivery. Hovione was the first Chemical/
Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360,
EFCG and participates actively in industry quality improvement initiatives to
lead new global industry standards.
About Zerion Pharma A/S
Zerion develops proprietary drug formulations and offers the Dispersome(R)
technology to established pharma companies as a means to solve their most
challenging drug solubility problems. By applying the Dispersome® technology,
the solubility of poorly soluble, oral drugs is greatly enhanced, which
improves their bioavailability and therapeutic outcomes for the patients.
Zerion was established in 2019 as a spinout from the University of Copenhagen
based on almost a decade of research. (Dispersome® is a trademark of Zerion
Pharma A/S)
For more information, please visit www.hovione.com or contact:
Vanessa Romeu | Communications Director | vromeu@hovione.com |Tel.: +351 21 982
9000
Logo -
https://mma.prnewswire.com/media/1883542/Hovione_and_Zerion_Pharma_Logos.jpg
Source: Hovione
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。